4.7 Review

The yin and yang functions of extracellular ATP and adenosine in tumor immunity

期刊

CANCER CELL INTERNATIONAL
卷 20, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12935-020-01195-x

关键词

Extracellular adenosine triphosphate; Adenosine; CD39; CD73; Tumor immunity

类别

资金

  1. National Natural Science Foundation [81500123, 81270598, 81473486, 81770210]
  2. Key Research and Development Projects of Shandong Province [2017G006005, 2018CXGC1213]
  3. Technology Development Projects of Shandong Province [2017GSF18189]
  4. Promotive Research Fund for Excellent Young and Middle-aged Scientists of Shandong Province [BS2013YY003]
  5. Natural Science Foundations of Shandong Province [ZR2016HP12]
  6. Taishan Scholar Program of Shandong Province
  7. Shandong Provincial Engineering Research Center of Lymphoma
  8. Key Laboratory for Kidney Regeneration of Shandong Province
  9. Academic promotion programme of Shandong First Medical University

向作者/读者索取更多资源

Extracellular adenosine triphosphate (eATP) and its main metabolite adenosine (ADO) constitute an intrinsic part of immunological network in tumor immunity. The concentrations of eATP and ADO in tumor microenvironment (TME) are controlled by ectonucleotidases, such as CD39 and CD73, the major ecto-enzymes expressed on immune cells, endothelial cells and cancer cells. Once accumulated in TME, eATP boosts antitumor immune responses, while ADO attenuates immunity against tumors. eATP and ADO, like yin and yang, represent two opposite aspects from immune-activating to immune-suppressive signals. Here we reviewed the functions of eATP and ADO in tumor immunity and attempt to block eATP hydrolysis, ADO formation and their contradictory effects in tumor models, allowing the induction of effective anti-tumor immune responses in TME. These attempts documented that therapeutic approaches targeting eATP/ADO metabolism and function may be effective methods in cancer therapy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

An Extended Prognostic Index of the ISSWM Score Based on Thyroid Complications in Waldenstrom Macroglobulinemia/Lymphoplasmacytoid Lymphoma

Xinting Hu, Hua Wang, Dai Yuan, Huiting Qu, Ying Li, Na Wang, Xianghua Wang, Xin Liu, Hongzhi Xu, Ya Zhang, Xin Wang

Summary: This study found a significant correlation between thyroid complications and unfavorable prognosis in WM/LPL patients. Thyroid complications were identified as independent prognostic indicators and incorporating them into the ISSWM score improved risk stratification and prognostic prediction. Subclinical hypothyroidism at an early stage predicted unfavorable outcomes.

FRONTIERS IN ONCOLOGY (2022)

Article Oncology

Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia

Zheng Tian, Ming Liu, Xiaosheng Fang, Xiangxiang Zhou, Peipei Li, Ying Li, Lingyan Zhang, Fang Liu, Ya Zhang, Xin Wang

Summary: Chronic lymphocytic leukemia (CLL) exhibits heterogeneity between Chinese and European patients. In China, CLL patients have an earlier age of onset and younger patients have a higher relapse rate compared to elderly patients. Novel risk score models are developed to optimize the risk assessment and provide insights for individualized diagnosis and treatment of CLL patients.

FRONTIERS IN ONCOLOGY (2022)

Review Oncology

m6A binding protein YTHDF2 in cancer

Xiaomin Chen, Xiangxiang Zhou, Xin Wang

Summary: YT521-B homology domain family member 2 (YTHDF2) is a protein that plays a role in various biological processes, including embryonic development, immune response, and tumor progression. It is involved in the proliferation, apoptosis, invasion, and migration of tumor cells, and modulates signaling pathways through m(6)A modification.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2022)

Review Oncology

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives

Zhuoya Yu, Xiangxiang Zhou, Xin Wang

Summary: Metabolic reprogramming, a hallmark of cancer progression, supports tumorigenesis and tumor progression by allowing cells to uptake essential nutrients and altering metabolic pathways to meet increased demands for energy and biosynthetic precursors. Activated oncogenes coordinate with altered metabolism to control cell-autonomous pathways, potentially leading to tumorigenesis. Targeting metabolic features of hematologic malignancies has shown promising therapeutic potential in both clinical and preclinical studies.

CANCER RESEARCH (2022)

Article Hematology

Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi-center, single-arm, open-label, phase 2 study

Wei Xu, Keshu Zhou, Tingyu Wang, Shenmiao Yang, Lihong Liu, Yu Hu, Wei Zhang, Kaiyang Ding, Jianfeng Zhou, Sujun Gao, Bing Xu, Zunmin Zhu, Ting Liu, Huilai Zhang, Jianda Hu, Chunyan Ji, Shunqing Wang, Zhongjun Xia, Xin Wang, Yan Li, Yongping Song, Shuo Ma, Xinran Tang, Bin Zhang, Jianyong Li

Summary: Orelabrutinib demonstrated significant efficacy and safety in patients with refractory or relapsed CLL/SLL, with an overall response rate of 92.5%. The median progression-free survival had not been reached at a 32.3-month median follow-up. Moreover, Orelabrutinib showed promising response in patients with high prognostic risks.

AMERICAN JOURNAL OF HEMATOLOGY (2023)

Article Oncology

Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study

Huishou Fan, Weida Wang, Ya Zhang, Jianxiang Wang, Tao Cheng, Lugui Qiu, Xin Wang, Zhongjun Xia, Gang An

Summary: The objective of this study was to understand the current care paradigm and outcomes of patients with newly diagnosed multiple myeloma (NDMM) in China. The study found that novel agent-based regimens, first-line autologous stem cell transplantation (ASCT), and sustained minimal residual disease (MRD) negativity were associated with a superior outcome for NDMM patients.

CANCER BIOLOGY & MEDICINE (2023)

Article Cell Biology

PGD2 displays distinct effects in diffuse large B-cell lymphoma depending on different concentrations

Shunfeng Hu, Tiange Lu, Juanjuan Shang, Yiqing Cai, Mengfei Ding, Xiangxiang Zhou, Xin Wang

Summary: This study found that DLBCL patients have high concentration of serum PGD2 and low expression of PGD2 receptor CRTH2, which are associated with clinical features and prognosis. Moreover, high-concentration PGD2 can inhibit DLBCL progression by regulating cell proliferation, apoptosis, cell cycle, and invasion, as well as induce DNA damage and enhance the cytotoxicity of anti-tumor drugs. Additionally, HDAC inhibitors and CRTH2 inhibitors can modulate PGD2 production and enhance their anti-tumor effects. Overall, PGD2 and CRTH2 may serve as prognostic biomarkers and therapeutic targets in DLBCL.

CELL DEATH DISCOVERY (2023)

Article Oncology

CTP synthase 2 predicts inferior survival and mediates DNA damage response via interacting with BRCA1 in chronic lymphocytic leukemia

Xinting Hu, Yang Han, Jiarui Liu, Hua Wang, Zheng Tian, Xin Zhang, Ya Zhang, Xin Wang

Summary: In this study, it was found that the expression of CTPS2 was significantly upregulated in patients with CLL and was closely associated with poor prognostic indicators. Downregulation of CTPS2 in CLL cells inhibited cell proliferation, induced cell cycle arrest and increased apoptosis. Further research revealed that CTPS2 promoted CLL progression by regulating the DNA damage response and repair pathway through interaction with the BRCA1 protein. These findings suggest that targeting nucleotide metabolism could be a promising strategy for CLL treatment.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2023)

Article Oncology

Single-cell transcriptome analysis profiles the expression features of TMEM173 in BM cells of high-risk B-cell acute lymphoblastic leukemia

Yiqing Cai, Xiaomin Chen, Tiange Lu, Zhuoya Yu, Shunfeng Hu, Jiarui Liu, Xiangxiang Zhou, Xin Wang

Summary: The mRNA and protein levels of TMEM173 are increased in B-ALL patients, and its expression is higher in specific cells. Targeted activation of TMEM173 may provide new therapeutic strategies for B-ALL.

BMC CANCER (2023)

Article Genetics & Heredity

PAX5 aberrant expression incorporated in MIPI-SP risk scoring system exhibits additive value in mantle cell lymphoma

Xin Zhang, Yang Han, Yu Nie, Yujie Jiang, Xiaohui Sui, Xueling Ge, Fang Liu, Ya Zhang, Xin Wang

Summary: This study reveals the prognostic value of PAX5 in mantle cell lymphoma and establishes a new risk scoring system, MIPI-SP, which outperforms the MIPI score in predicting prognosis.

JOURNAL OF MOLECULAR MEDICINE-JMM (2023)

Article Oncology

Prognosis and complications of patients with primary gastrointestinal diffuse large B-cell lymphoma: Development and validation of the systemic inflammation response index-covered score

Yurou Chu, Yingyue Liu, Yujie Jiang, Xueling Ge, Dai Yuan, Mei Ding, Huiting Qu, Fang Liu, Xiangxiang Zhou, Xin Wang

Summary: This study evaluated the predictive value of systemic inflammation response index (SIRI) in primary gastrointestinal diffuse large B-cell lymphoma (PGI-DLBCL) patients and established a highly discriminating risk prediction model. The presence of high pretreatment SIRI was significantly associated with poorer survival and identified as an independent prognostic factor. A new model, SIRI-PI, showed superior performance in predicting high-risk assessment compared to NCCN-IPI.

CANCER MEDICINE (2023)

Article Hematology

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren -Bin Zhao, Bin Zhang, Ya -Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu

Summary: Orelabrutinib demonstrates significant efficacy and tolerability in patients with relapsed or refractory mantle cell lymphoma, with a high overall response rate and median progression-free survival.

BLOOD ADVANCES (2023)

Article Cell Biology

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis

Yiqing Cai, Liemei Lv, Tiange Lu, Mengfei Ding, Zhuoya Yu, Xiaomin Chen, Xiangxiang Zhou, Xin Wang

Summary: Metabolic reprogramming, specifically dysregulation of glutamine metabolism, plays a crucial role in tumorigenesis, microenvironment remodeling, and therapeutic resistance in DLBCL. High levels of glutamine are associated with poor clinical outcomes, while the derivative of glutamine, a-KG, is negatively correlated with invasiveness features. Treatment with DM-aKG significantly inhibits tumor growth by inducing apoptosis and non-apoptotic cell death. The study highlights the potential use of a-KG as a novel therapeutic strategy for DHL patients.

CELL DEATH DISCOVERY (2023)

Article Nutrition & Dietetics

Derivation and validation of a nutrition-covered prognostic scoring system for extranodal NK/T-cell lymphoma

Tiange Lu, Xue Shi, Xueling Ge, Ying Li, Yiqing Cai, Xiaomin Chen, Shunfeng Hu, Mei Ding, Xiaosheng Fang, Fang Liu, Xiangxiang Zhou, Xin Wang

Summary: In this study, the significance of nutritional status in extranodal NK/T-cell lymphoma (ENKTL) was explored, and a new scoring system (CONUT-PINK-E) was developed to assess patients' nutritional status and prognosis. The results showed that CONUT-PINK-E could independently predict patients' overall survival and progression-free survival, and presented superior discrimination and clinical benefit compared to current models.

FRONTIERS IN NUTRITION (2023)

Article Biochemistry & Molecular Biology

KIAA1429-mediated m6A modification of CHST11 promotes progression of diffuse large B-cell lymphoma by regulating Hippo-YAP pathway

Xiaomin Chen, Tiange Lu, Yiqing Cai, Yang Han, Mengfei Ding, Yurou Chu, Xiangxiang Zhou, Xin Wang

Summary: The study reveals that m6A modification mediated by KIAA1429 plays a role in DLBCL progression by regulating CHST11 expression and inactivating the Hippo-YAP pathway. KIAA1429 has the potential to be a predictive biomarker and therapeutic target for DLBCL.

CELLULAR & MOLECULAR BIOLOGY LETTERS (2023)

暂无数据